XML 117 R60.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Acquisitions, Divestitures, Assets and Liabilities Held for Sale, Licensing Arrangements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Privately Held Investment - R & D and Collaborative Arrangements (Detail) - USD ($) |  |  | 1 Months Ended | 3 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | ---
Jan. 01, 2018 | Oct. 31, 2016 | Dec. 31, 2016 | May 31, 2016 | Apr. 30, 2016 | Jan. 31, 2016 | Apr. 01, 2018 | Apr. 02, 2017 | Dec. 31, 2014 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2013
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues | [1] |  |  |  |  |  |  |  |  |  | $ 53,647,000,000 | $ 52,546,000,000 | $ 52,824,000,000 |
Cost of sales | [1],[2] |  |  |  |  |  |  |  |  |  | (11,248,000,000) | (11,228,000,000) | (12,322,000,000) |
Selling, informational and administrative expenses | [1],[2] |  |  |  |  |  |  |  |  |  | (14,455,000,000) | (14,804,000,000) | (14,844,000,000) |
Research and development expenses | [1],[2] |  |  |  |  |  |  |  |  |  | (8,006,000,000) | (7,683,000,000) | (7,892,000,000) |
Other income/(deductions)—net | [1] |  |  |  |  |  |  |  |  |  | (2,116,000,000) | (1,416,000,000) | (3,794,000,000) |
NovaQuest Co-Investment Fund II, L.P. [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amount refunded to NovaQuest |  |  |  | $ 31,300,000 |  |  |  |  |  |  |  |  |  |
Maximum funding amount |  |  |  |  | $ 250,000,000 |  |  |  |  |  |  |  |  |
Percentage of costs to be reimbursed |  |  |  |  | 40.00% |  |  |  |  |  |  |  |  |
Reduction to research and development expense |  |  |  |  |  |  |  |  |  |  |  |  | 180,300,000 |
NovaQuest Co-Investment Fund V, L.P. [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum funding amount |  |  |  |  |  | $ 200,000,000 |  |  |  |  |  |  |  |
Percentage of costs to be reimbursed |  |  |  |  |  | 100.00% |  |  |  |  |  |  |  |
Reduction to research and development expense |  |  |  |  |  |  |  |  |  |  | 57,600,000 | 72,100,000 | 46,600,000 |
Research and development, contingent payments, maximum exposure |  |  |  |  |  | $ 267,000,000 |  |  |  |  |  |  |  |
Term over which funding will be received |  |  |  |  |  | 3 years 3 months |  |  |  |  |  |  |  |
RPI Finance Trust [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum funding amount |  |  |  |  |  |  | $ 300,000,000 |  |  |  |  |  |  |
Percentage of costs to be reimbursed |  |  |  |  |  |  | 100.00% |  |  |  |  |  |  |
Reduction to research and development expense |  |  |  |  |  |  |  |  |  |  | 99,300,000 | 75,600,000 | 44,900,000 |
Research and development, contingent payments, maximum exposure |  |  |  |  |  |  | $ 250,000,000 |  |  |  |  |  |  |
Collaborative Arrangement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  | 4,409,000,000 | 3,533,000,000 | 2,405,000,000 |
Cost of sales | [3] |  |  |  |  |  |  |  |  |  | (296,000,000) | (329,000,000) | (315,000,000) |
Selling, informational and administrative expenses | [4] |  |  |  |  |  |  |  |  |  | (90,000,000) | (54,000,000) | (5,000,000) |
Research and development expenses | [5] |  |  |  |  |  |  |  |  |  | 162,000,000 | 222,000,000 | 64,000,000 |
Other income/(deductions)—net | [6] |  |  |  |  |  |  |  |  |  | 281,000,000 | 249,000,000 | 542,000,000 |
Upfront payments and milestone payments |  |  |  |  |  |  |  |  |  |  | 50,000,000 | 15,000,000 | 15,000,000 |
Collaborative Arrangement [Member] | Eli Lilly & Company [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds received from upfront payments and milestone payments |  |  |  |  |  |  |  |  |  |  | 98,000,000 | 147,000,000 | 120,000,000 |
Deferred milestone revenue recognized |  |  |  |  |  |  |  |  |  |  | 37,000,000 |  |  |
Collaborative Arrangement [Member] | Merck KGaA [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative arrangement sales based milestones payments |  |  |  |  |  |  |  |  |  |  |  | 140,000,000 |  |
Potential milestone payments |  |  |  |  |  |  |  |  |  | $ 2,000,000,000 |  |  |  |
Collaborative Arrangement [Member] | Merck [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds received from upfront payments and milestone payments |  |  |  |  |  |  |  |  |  |  | $ 40,000,000 | 150,000,000 |  |
Collaborator's revenue and expense ownership percentage |  |  |  |  |  |  |  |  |  |  | 60.00% |  |  |
Company's revenue and expense ownership percentage |  |  |  |  |  |  |  |  |  |  | 40.00% |  |  |
Collaborative Arrangement [Member] | Merck [Member] | Other Nonoperating Income (Expense) [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds received from upfront payments and milestone payments |  |  |  |  |  |  |  |  | $ 90,000,000 |  | $ 40,000,000 |  |  |
Milestone payment due to be received |  |  |  |  |  |  |  | $ 40,000,000 |  |  |  | 60,000,000 |  |
Deferred milestone revenue recognized |  |  |  |  |  |  |  | 90,000,000 |  |  |  |  |  |
Collaborative Arrangement [Member] | Other Noncurrent Liabilities [Member] | Eli Lilly & Company [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred milestone revenue recognized |  |  |  |  |  |  |  |  |  |  | 8,000,000 |  |  |
Collaborative Arrangement [Member] | Other Noncurrent Liabilities [Member] | Merck [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred milestone payment |  |  |  |  |  |  |  |  |  |  |  | 60,000,000 |  |
Collaborative Arrangement [Member] | Deferred Revenue [Member] | Eli Lilly & Company [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds received from upfront payments and milestone payments |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 200,000,000
Collaborative Arrangement [Member] | Other current liabilities [Member] | Eli Lilly & Company [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred milestone revenue recognized |  |  |  |  |  |  |  |  |  |  | 30,000,000 |  |  |
Revenues [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues | [7] |  |  |  |  |  |  |  |  |  | 571,000,000 | 606,000,000 | 659,000,000 |
Alliance Revenues [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues | [8] |  |  |  |  |  |  |  |  |  | $ 3,838,000,000 | $ 2,927,000,000 | $ 1,746,000,000 |
Royalty revenue, term |  |  | 36 months |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Upfront Cash Payment [Member] | Merck KGaA [Member] | Research and Development Expense [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payments and milestone payments |  |  |  |  |  |  |  |  |  | $ 850,000,000 |  |  |  |
Revenues [Member] | Difference between Revenue Guidance in Effect before and after Topic 606 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cumulative effect on retained earnings, before tax |  | $ 584,000,000 |  |  |  |  |  | 584,000,000 |  |  |  |  |  |
Revenues [Member] | Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Collaborative Arrangement [Member] | Merck [Member] | Other Nonoperating Income (Expense) [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred milestone revenue recognized |  |  |  |  |  |  |  | 85,000,000 |  |  |  |  |  |
Revenues [Member] | Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Collaborative Arrangement [Member] | Other Noncurrent Liabilities [Member] | Merck [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred milestone payment |  |  |  |  |  |  |  | 60,000,000 |  |  |  |  |  |
Revenues [Member] | Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Collaborative Arrangement [Member] | Deferred Revenue [Member] | Eli Lilly & Company [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred milestone revenue recognized |  |  |  |  |  |  |  | $ 107,000,000 |  |  |  |  |  |
[1] | Amounts may not add due to rounding.
[2] | Exclusive of amortization of intangible assets, except as disclosed in Note 1L. Basis of Presentation and Significant Accounting Policies: Amortization of Intangible Assets, Depreciation and Certain Long-Lived Assets.
[3] | Primarily relates to amounts paid to collaboration partners for their share of net sales or profits earned in collaboration arrangements where we are the principal in the transaction, and cost of sales associated with inventory purchased from our partners.
[4] | Represents net reimbursements to our partners for selling, informational and administrative expenses incurred.
[5] | Primarily relates to upfront payments and pre-approval milestone payments earned by our partners as well as net reimbursements. The upfront and milestone payments were as follows: $50 million in 2018, $15 million in 2017 and $15 million in 2016. Our collaboration with Lilly (see below) also includes reimbursements of $98 million in 2018, $147 million in 2017 and $120 million in 2016.
[6] | Primarily relates to royalties from our collaboration partners. The decrease in 2017 is due to the October 31, 2016 expiration of our 36 month royalty arrangement on sales of Enbrel in the U.S. and Canada, partially offset by a full year of royalties earned in 2017, versus a partial year in 2016, on Xtandi ex-U.S. sales.
[7] | Represents sales to our partners of products manufactured by us.
[8] | Substantially all relates to amounts earned from our partners under co-promotion agreements. The increases in 2018 and 2017 reflect increases in alliance revenues from Eliquis and Xtandi.

X
- Definition Collaborative Arrangement, Collaborator's Revenue and Expense Ownership Percentage + References No definition available. + Details
Name: | pfe_CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage
Namespace Prefix: | pfe_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Arrangement, Company's Revenue and Expense Ownership Percentage + References No definition available. + Details
Name: | pfe_CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage
Namespace Prefix: | pfe_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Arrangement, Contingent Payments, Maximum Exposure + References No definition available. + Details
Name: | pfe_CollaborativeArrangementContingentPaymentsMaximumExposure
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative Arrangement, Deferred Milestone Payment + References No definition available. + Details
Name: | pfe_CollaborativeArrangementDeferredMilestonePayment
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaborative Arrangement, Deferred Milestone Revenue Recognized + References No definition available. + Details
Name: | pfe_CollaborativeArrangementDeferredMilestoneRevenueRecognized
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaborative Arrangement, Milestone Payment, Receivable + References No definition available. + Details
Name: | pfe_CollaborativeArrangementMilestonePaymentReceivable
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Collaborative Arrangement, Refund to Collaborators + References No definition available. + Details
Name: | pfe_CollaborativeArrangementRefundtoCollaborators
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflow to our partners for payments made upfront as part of a collaborative arrangement and the payments upon the achievement of milestones. + References No definition available. + Details
Name: | pfe_CollaborativeArrangementUpfrontAndMilestonePayments
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Prepayments and Payments to Collaborators + References No definition available. + Details
Name: | pfe_PrepaymentsandPaymentstoCollaborators
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Research and Development Arrangement, Contingent Payments, Maximum Exposure + References No definition available. + Details
Name: | pfe_ResearchandDevelopmentArrangementContingentPaymentsMaximumExposure
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Research and Development Arrangement, Funding to Offset Costs Incurred + References No definition available. + Details
Name: | pfe_ResearchandDevelopmentArrangementFundingtoOffsetCostsIncurred
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Research and Development Arrangement, Maximum Funding Amount + References No definition available. + Details
Name: | pfe_ResearchandDevelopmentArrangementMaximumFundingAmount
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Research and Development Arrangement, Maximum Funding Amount, Term + References No definition available. + Details
Name: | pfe_ResearchandDevelopmentArrangementMaximumFundingAmountTerm
Namespace Prefix: | pfe_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Research and Development Arrangement, Percentage of Costs to be Reimbursed + References No definition available. + Details
Name: | pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed
Namespace Prefix: | pfe_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Royalty Revenue, Term + References No definition available. + Details
Name: | pfe_RoyaltyRevenueTerm
Namespace Prefix: | pfe_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(a),(d)) -URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227 + Details
Name: | us-gaap_CostOfGoodsAndServicesSold
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of the cumulative effect on retained earnings before related income tax effect. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 860 -SubTopic 50 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=68078379&loc=d3e122869-111746 + Details
Name: | us-gaap_CumulativeEffectOnRetainedEarningsBeforeTax1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of income (expense) related to nonoperating activities, classified as other. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.9) -URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227 + Details
Name: | us-gaap_OtherNonoperatingIncomeExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Cash received from collaborators during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585 + Details
Name: | us-gaap_ProceedsFromCollaborators
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 330 -SubTopic 10 -Section 30 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227 + Details
Name: | us-gaap_SellingGeneralAndAdministrativeExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=pfe_NovaQuestCoInvestmentFundIIL.P.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=pfe_NovaQuestCoInvestmentFundVL.P.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=pfe_RPIFinanceTrustMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=pfe_EliLillyCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=pfe_MerckKGaAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=pfe_MerckMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=pfe_DeferredRevenueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementProductAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementCopromotionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=pfe_CollaborativeArrangementUpfrontCashPaymentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |